CKD-337(2) Drug-drug Interaction Study

NCT ID: NCT02422030

Last Updated: 2017-08-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-17
• Study Completion Date: 2015-04-30

Brief Summary

The purpose of this study is to evaluate the pharmacokinetic interaction between Atorvastatin and Fenofibric acid.

Detailed Description

This study is a randomized, open-label, multiple dosing, 3-way crossover design to evaluate the drug-drug interaction between Atorvastatin (Lipitor) and Fenofibric (Trilipix) acid in healthy male subjects. Subjects will receive repeated dose of Atorvastatin (40mg*1Tab/day) or Fenofibric acid (135mg*1Cap/day) or Atorvastatin (40mg*1Tab/day)/Fenofibric acid (135mg*1Cap/day). Each treatment period was separated by a washout period of at least 8 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group1: TreatmentA+TreatmentB+TreatmentC

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Group2: TreatmentC+TreatmentA+TreatmentB

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Group3: TreatmentB+TreatmentC+TreatmentA

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Group4: TreatmentC+TreatmentB+TreatmentA

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Group5: TreatmentB+TreatmentA+TreatmentC

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Group6: TreatmentA+TreatmentC+TreatmentB

TreatmentA: Atorvastatin 40m\*1T/day, TreatmentB: Fenofibric acid 135mg\*1Cap/day, TreatmentC: Atorvastatin 40m\*1T/day and Fenofibric acid 135mg\*1Cap/day. Each treatment period was separated by a washout period of at least 8days.

Group Type: EXPERIMENTAL

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Interventions

Lipitor Tab. 40mg

Intervention Type: DRUG

Trilipix 135mg

Intervention Type: DRUG

Other Intervention Names

Atorvastatin 40mg; Fenofibric acid 135mg

Eligibility Criteria

Inclusion Criteria

• Healthy man older than 19 years at the time of screening.
• BMI more than 17.5kg / m2 and less than 30.5kg / m2 and weight more than 55kg
• Subject without congenital or chronic diseases and no psychotic symptoms or findings from the medical examination.
• Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as ECG test.
• Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital IRB.
• Subjects who are able to comply with all scheduled visits, laboratory tests and other procedures.

Exclusion Criteria

1. Subject who has a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)

2. Subject who has a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.

3. Showing the value that corresponds to following laboratory parameters: AST or AST or CK > 2* upper limit of normal range.

4. Alcohol > 210g/week, within 6 months prior to the screening.

5. Taking the medication involved in other clinical trials within two months before the first dose medication characters.

6. Sitting Systolic Blood Pressure ≥ 140 mmHg, Diastolic Blood Pressure ≥ 90 mmHg at the time of screening.

7. History of alcohol or drug abuse, within 1 year

8. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.

9. Smoker (> 20cigarettes/day)

10. Subjects who takes ETC or OTC medicine within 10days before the first IP administration.

11. Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.

12. Subject who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.

13. Subject with serious history of hypersensitivity or allergy to investigational product.

14. Active liver disease.

15. Muscle disease.

16. Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.

17. Patients with severe hepatic impairment or Gallbladder Disease.

18. Patients with moderate to severe renal impairment.

19. Patients experienced allergy or phototoxicity during treatment with fibrate or ketoprofen.

20. Subjects who is not able to comply with guidelines described in the protocol.

21. Subjects who is determined by investigator's decision as unsuitable for clinical trial participation.

• Minimum Eligible Age: 19 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Min Gul Kim

Role: PRINCIPAL_INVESTIGATOR

Chonbuk National University Hospital

Locations

Chonbuk National University Hospital

Deokjin-gu, Jeonju-si, Jeollabuk-do, South Korea

Countries

South Korea

Other Identifiers

146DDI14030

Identifier Type: -

Identifier Source: org_study_id